Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer
Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM). Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper. (Daniel Öhlund)ORCID-id: 0000-0002-1353-316X
Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM). Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper. (Daniel Öhlund)
Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM). Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper. (Daniel Öhlund)
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi. (Niklas Arnberg)
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Cancer immunology research, ISSN 2326-6066, Vol. 11, nr 1, s. 72-92Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Pancreatic ductal adenocarcinoma (PDAC) is characterized by rich deposits of extracellular matrix (ECM), affecting the pathophysiology of the disease. Here, we identified galectin 4 (gal 4) as a cancer cell produced protein deposited into the ECM of PDAC tumors and detected high circulating levels of gal 4 in PDAC patients. In orthotopic transplantation experiments we observed increased infiltration of T-cells and prolonged survival in immunocompetent mice transplanted with cancer cells with reduced expression of gal 4. Increased survival was not observed in immunodeficient RAG1-/- mice, demonstrating that the effect was mediated by the adaptive immune system. Furthermore, by performing single-cell RNA-sequencing we found that the myeloid compartment and cancer-associated fibroblast (CAF) subtypes were altered in the transplanted tumors. Reduced gal 4 expression was associated with higher proportion of myofibroblastic CAFs and reduced numbers of inflammatory CAFs. We also found higher proportions of M1 macrophages, T-cells and antigen presenting dendritic cells in tumors with reduced gal 4 expression. Using a co-culture system, we observed that extracellular gal 4 induced apoptosis in T-cells by binding N-glycosylation residues on CD3 epsilon/delta. Hence, we show that gal 4 is involved in immune evasion and identify gal 4 as a promising drug target for overcoming immunosuppression in PDAC. 

Ort, förlag, år, upplaga, sidor
American Association for Cancer Research , 2023. Vol. 11, nr 1, s. 72-92
Nyckelord [en]
Galectin 4, pancreatic cancer, immunosuppression, extracellular matrix, drug target
Nationell ämneskategori
Cancer och onkologi
Forskningsämne
immunologi; medicin; onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-201042DOI: 10.1158/2326-6066.CIR-21-1088PubMedID: 36478037Scopus ID: 2-s2.0-85145492684OAI: oai:DiVA.org:umu-201042DiVA, id: diva2:1711212
Ingår i projekt
Tumörstromat som läkemedelsmål vid pankreascancer, Vetenskapsrådet
Forskningsfinansiär
Stiftelsen för internationalisering av högre utbildning och forskning (STINT), PT2015-6432Cancerfonden, AMP17-877, LP18-2202, LP20-2257, LP 21-2298Vetenskapsrådet, 2017-01531Kempestiftelserna, JCK-1301, SMK-1765Svenska läkaresällskapet, SLS-890521, SLS-786661, SLS-691681, SLS-591551Västerbottens läns landsting, RV-930167, VLL-643451, VLL-832001SjöbergstiftelsenKnut och Alice Wallenbergs StiftelseMarianne och Marcus Wallenbergs Stiftelse, MMW 2020.0189Cancerfonden, CAN 2017/332, CAN 2017/827, 20 1339 PjFCancerfonden, AMP-18-919Knut och Alice Wallenbergs Stiftelse
Anmärkning

Originally included in thesis in manuscript form. 

Tillgänglig från: 2022-11-16 Skapad: 2022-11-16 Senast uppdaterad: 2023-10-18Bibliografiskt granskad
Ingår i avhandling
1. Immunosuppressive and metastasis-promoting matrisome proteins in pancreatic cancer: the role of galectin 4 and SERPINB5
Öppna denna publikation i ny flik eller fönster >>Immunosuppressive and metastasis-promoting matrisome proteins in pancreatic cancer: the role of galectin 4 and SERPINB5
2022 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Immunosuppresiva och metastasfrämjande matrsomproteiner i pankreascancer : effekten av galectin-4 och SERPINB5
Abstract [en]

In Sweden 1200-1300 people are diagnosed with pancreatic ductal adenocarcinoma (PDAC) every year. Late diagnosis, together with poor treatment response and resistance to checkpoint inhibitor immunotherapy, contributes to the poor prognosis of the disease. 

PDAC is characterized by abundant deposits of extracellular matrix, which mainly includes structural proteins including collagens, proteoglycans, cell-binding glycoproteins, carbohydrates, and secreted proteins, all constituting the matrisome of the tumor. The matrisome protects cancer cells and affects the outcome. Several highly expressed matrisome proteins are involved in oncogenesis, including the processes of immunosuppression and metastasis formation, therefore contributing to the poor prognosis. In this thesis the pathophysiological role of several matrisome proteins in PDAC tumor progression was studied. Unbiased analysis of matrisome proteins in PDAC tumors revealed increased levels of cancer cell-derived secreted proteins compared to normal healthy control tissue. Subsequently, differentially expressed candidate proteins, with known cellular functions in other disease but hitherto uncharacterized role in PDAC progression, were selected.

Serine protease inhibitor clade B member 5 (SERPINB5), agrin, and cystatin B (CSTB), were selected for the study described in paper I based on their known roles in the metastasis formation process in other types of cancers. SERPINB5, agrin and CSTB were found to increase metastasis in models of PDAC by affecting epithelial to mesenchymal transition, ECM degradation and extravasation. In PDAC tumors, high levels of extracellular SERPINB5 correlated to reduced overall survival.  

Galectin 4 (Gal 4) was selected for the study described in paper II based on its known immunosuppressive effects. Gal 4 is highly expressed in PDAC and was found to inhibit T cell infiltration and induce apoptosis in CD8+ T cells by binding to CD3 on the surface of T cells. Gal 4 was associated with better survival in PDAC patients and correlated to higher activation and cytolytic effect of CD8+ T cells.

The relation between gal 4 and other immunosuppressive proteins was studied in paper III. Analysis of available datasets revealed that gal 4 expression correlates with other cancer cell-derived immunosuppressive proteins of the galectin family, galectin 3 and galectin 9, while negatively correlating with the stroma-derived factors galectin-1 and TGFBI.

Findings in this thesis show that targeting of matrisome proteins in PDAC can be a promising therapy strategy. Blocking extracellular SERPINB5 could result in reduced metastasis and increased survival. Blocking intracellular gal 4 could increase anti-tumor immunity and synergize with checkpoint inhibition therapy.

The identified co-expression and coregulation of different immunosuppressive proteins indicate that different tumors can be classified based on their predominant immunosuppressive mechanisms. Following this classification in individual patients, combinations of therapies against different immunosuppressive mechanisms could represent a promising strategy to introduce effective immunotherapies for PDAC patients.  

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2022. s. 87
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2207
Nyckelord
pancreatic cancer, galectin 4, immunotherapy, SERPINB5, metastasis, extracellular matrix, drug target
Nationell ämneskategori
Cancer och onkologi
Forskningsämne
onkologi; immunologi; medicin
Identifikatorer
urn:nbn:se:umu:diva-201043 (URN)978-91-7855-941-1 (ISBN)978-91-7855-942-8 (ISBN)
Disputation
2022-12-09, Hörsal B, 9 trappor, byggnad 1D, Umeå, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2022-11-18 Skapad: 2022-11-16 Senast uppdaterad: 2022-11-17Bibliografiskt granskad
2. The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer
Öppna denna publikation i ny flik eller fönster >>The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer
2023 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Identifiering och funktionell utvärdering av nya cancer-associerade fibroblast-subtyper och matrisomeproteiner i pankreascancer
Abstract [en]

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an extensive desmoplastic stroma. The stroma is the site of intricate communication between malignant cells and their surrounding environment. This tissue microenvironment (TME) is populated by a heterogenous mixture of cell types and extracellular matrix proteins. Distinct stromal elements confer tumour-restraining or tumour-promoting influences on tumorigenesis. Characterizing stromal composition therefore represents an opportunity to identify candidates for therapeutic intervention to facilitate improved clinical outcomes. In this thesis we identify galectin-4 as an extracellular matrix protein which is upregulated in PDAC. We find that galectin-4 exerts a pro-tumorigenic influence in PDAC through promoting immune suppression, highlighting its potential as a novel therapeutic target. We subsequently provide a comprehensive characterization of mesenchymal cell diversity in PDAC including cancer-associated fibroblasts (CAFs) which represent one of the dominant stromal cellular components. We identify inflammatory CAF (iCAF) and myofibroblastic CAF (myCAF) subtypes in addition to defining a novel interferon-response CAF (ifCAF) subtype. In addition, we demonstrate that pancreatic stellate cells (PSCs) are capable of forming iCAFs, myCAFs and ifCAFs in response to tumour-derived signals using an organoid-based co-culture model and define biological pathways regulating CAF subtype formation. We then perform a high-throughput drug-screen using this co-culture model to identify compounds which can suppress tumour growth indirectly through modifying CAFs. One such compound is GNF-5 which we show can suppress cancer cell proliferation indirectly through manipulating CAF phenotype. Taken together, this thesis augments our understanding of the composition of the PDAC stroma and identifies potential therapeutic targets as well as developing an approach to discover drugs which yield a therapeutic benefit through targeting the PDAC stroma.   

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2023. s. 122
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2259
Nyckelord
Cancer-associated fibroblast (CAF), Single-cell RNA sequencing (scRNAseq), Pancreatic ductal adenocarcinoma (PDAC), Tumor microenvironment (TME), Extracellular matrix (ECM), Organoid-based co-culture model, Drug-screen
Nationell ämneskategori
Cancer och onkologi
Forskningsämne
onkologi
Identifikatorer
urn:nbn:se:umu:diva-215330 (URN)9789180701747 (ISBN)9789180701754 (ISBN)
Disputation
2023-11-17, Betula, 6M, Norrlands universitetssjukhus, Umeå, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2023-10-26 Skapad: 2023-10-18 Senast uppdaterad: 2023-10-19Bibliografiskt granskad

Open Access i DiVA

fulltext(13580 kB)201 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 13580 kBChecksumma SHA-512
34355e3b7679f1a3e6b3d050d272c1b99a3c2edf68076e39a59c2f05160e05d9ba167b83fda846ce09b87c46212adc2689849f8c70f010ce8e31540f2bdae6ba
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Lidström, TommyCumming, JoshuaGaur, RahulFrängsmyr, LarsFranklin, OskarForsell, Mattias N. E.Arnberg, NiklasDongre, MiteshPatthey, CedricÖhlund, Daniel

Sök vidare i DiVA

Av författaren/redaktören
Lidström, TommyCumming, JoshuaGaur, RahulFrängsmyr, LarsFranklin, OskarForsell, Mattias N. E.Arnberg, NiklasDongre, MiteshPatthey, CedricÖhlund, Daniel
Av organisationen
Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Institutionen för strålningsvetenskaperInstitutionen för klinisk mikrobiologiInstitutionen för kirurgisk och perioperativ vetenskap
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 201 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 897 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf